The stripping of the legislation from the short-term funding package was described as a "missed opportunity" by the National ...

Ionis Pharma's olezarsen has become the first FDA-approved drug therapy for adults with familial chylomicronaemia syndrome ...

Eli Lilly's Zepbound has become the first drug to be FDA-approved for obstructive sleep apnoea (OSA), a sleep-related ...

Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Outgoing US President Joe Biden has proposed a dramatic expansion of Medicare coverage of obesity drugs, although it remains to be seen if it will survive under Donald Trump's new administration.

It was the day we’d all been waiting for. Rachel Reeves’ Autumn Budget felt like it had been on the horizon for a while. And it was great to see a commitment to the NHS, with an extra £22.6 ...

Field medical education before launch is linked to greater launch success, improving treatment adoption by up to 50%. New data also finds that biopharmas investing in pre-launch scientific ...

A leading IT industry organisation in the UK has called on the government to guarantee funding for digital transformation and cyber resilience in health and social care, saying it is vital not to ...

Faced with a cash crunch, Alligator Biosciences has said it plans to shed up to 70% of its workforce and focus all its attention on lead cancer drug mitazalimab as it prepares for phase 3 trials.

Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure. The European Commission revoked the conditional ...

Eli Lilly will spend $3 billion expanding a recently acquired manufacturing facility in Wisconsin to provide capacity for injectable products, including its fast-growing obesity and diabetes drugs.